News | April 30, 2026
Teva strikes $900M bet on breakthrough Tourette drug with Emalex buyout
The agreement could rise to $900 million if key commercial milestones are met
The agreement could rise to $900 million if key commercial milestones are met
The online platform is designed to go beyond clinical treatment, offering practical tools, lived-experience insights, and peer-informed support intended to reduce isolation and improve day-to-day coping
The US FDA has approved PONLIMSI (denosumab-adet) as a biosimilar to Prolia
Evogene said ChemPass AI was significantly expanded during 2025 through internal development and collaborations with Google Cloud
The funding will be spread over four years, with BXLS also eligible for regulatory and commercial milestones, plus royalties on worldwide sales
If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations
Duvakitug was well tolerated and safety was consistent with the induction study
HD causes cognitive, behavioral, and physical challenges, including involuntary movements known as HD chorea, which can disrupt daily life
The findings, from the SPACE study, paved the way for FDA approval of AJOVY for pediatric patients aged 6-17 years weighing 45 kilograms
The investigational therapy uses SteadyTeq, a proprietary copolymer technology from Medincell designed to release olanzapine steadily over time
Subscribe To Our Newsletter & Stay Updated
